Optimization of Self-complementary AAV Vectors for Liver-directed Expression Results in Sustained Correction of Hemophilia B at Low Vector Dose
Open accessThe DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
Self-complementary adeno-associated virus (scAAV) vectors can significantly minimize the vector load required to achieve sustained transgene expression. In this study, transcriptional regulatory elements were systematically screened to produce constitutive and liver-specific scAAV factor IX (FIX) expression cassettes. In addition, optimization of GC content, cis- regulatory elements, and codon usage in the human FIX (hFIX) transgene increased expression 4-20-fold. A vector was developed that was capable of expressing high FIX levels in comparison with the single-stranded (ss) AAV vector used in a recent clinical trial. The ssAAV and scAAV vectors display different transgene expression and genome stability patterns in the liver, as determined by immunohistochemical staining, in situ messenger RNA (mRNA) hybridization and vector genome quantitation. The ssAAV2 vector promoted strong FIX expression in only a subset of hepatocytes. The scAAV2-hFIX vector showed widespread ( approximately 80% of hepatocytes), moderate FIX expression levels similar to normal livers with correction of coagulation function in FIX-deficient mice. The ability of low dose scAAV-FIX vectors to achieve near-physiological expression may circumvent inflammatory responses in the liver. In addition to providing an improved scAAV vector for potential application in future hemophilia B clinical trials and liver-directed gene delivery, these studies underscore the need for rigorous analysis and optimization of vector genome cassettes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The bGHpolyA turned out to be the strongest for the FIX gene expression, outperforming other polyA sequences such as the synthetic polyA, mouse β-globin pA, rabbit β-globin pA, and H4-based pA [143].”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [143]
In the citing paper
“Especially, the strong MVM intron-1 of the viral capsid protein (VP-1) of only 67-to-97 bp can increase the transcript expression by 10× [143].”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [143]
In the citing paper
“Strikingly, introducing the Minute virus of mice (MVM) intron between promoter and transgene has been reported to increase 80-fold of transgene expression in liver cells compared to intron-null AAV [24].”
From Designing and optimizing AAV-mediated gene therapy for neurodegenerative diseases: from bench to bedside (2024) · cites this paper as [24]
Citations
Cites
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Xiao, X., Li, J., & Samulski, R. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.3.2224-2232.1998 · Cited by 1,381
Self-citationKay, M. A., Manno, C. S., Ragni, M. V., Larson, P. J., Couto, L. B., McClelland, A., Glader, B., Chew, A. J., J Tai, S., Herzog, R. W., et al. (2000) · Nature Genetics · doi:10.1038/73464 · Cited by 1,022
Ferrari, F. K., Samulski, T., Shenk, T., & Samulski, R. J. (1996) · Journal of Virology · doi:10.1128/jvi.70.5.3227-3234.1996 · Cited by 761
Self-citationMcCarty, D., Monahan, P., & Samulski, R. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301514 · Cited by 735
Self-citationFisher, K. J., Gao, G. P., Weitzman, M. D., DeMatteo, R., Burda, J. F., & Wilson, J. M. (1996) · Journal of Virology · doi:10.1128/jvi.70.1.520-532.1996 · Cited by 547
McCarty, D. M., Fu, H., Monahan, P. E., Toulson, C. E., Naik, P., & Samulski, R. J. (2003) · Gene Therapy · doi:10.1038/sj.gt.3302134 · Cited by 547
Self-citationCodon usage limitation in the expression of HIV-1 envelope glycoprotein
Haas, J., Park, E.-C., & Seed, B. (1996) · Current Biology · doi:10.1016/s0960-9822(02)00482-7 · Cited by 532
High Guanine and Cytosine Content Increases mRNA Levels in Mammalian Cells
Kudla, G., Lipinski, L., Caffin, F., Helwak, A., & Zylicz, M. (2006) · PLoS Biology · doi:10.1371/journal.pbio.0040180 · Cited by 476
Nathwani, A. C., Gray, J. T., Ng, C. Y. C., Zhou, J., Spence, Y., Waddington, S. N., Tuddenham, E. G. D., Kemball-Cook, G., McIntosh, J., Boon-Spijker, M., et al. (2006) · Blood · doi:10.1182/blood-2005-10-4035 · Cited by 421
Wang, Z., Ma, H.-I., Li, J., Sun, L., Zhang, J., & Xiao, X. (2003) · Gene Therapy · doi:10.1038/sj.gt.3302133 · Cited by 367
Unrestricted Hepatocyte Transduction with Adeno-Associated Virus Serotype 8 Vectors in Mice
Nakai, H., Fuess, S., Storm, T. A., Muramatsu, S.-I., Nara, Y., & Kay, M. A. (2005) · Journal of Virology · doi:10.1128/jvi.79.1.214-224.2005 · Cited by 327
A Coagulation Factor IX-Deficient Mouse Model for Human Hemophilia B
Lin, H.-F., Maeda, N., Smithies, O., Straight, D. L., & Stafford, D. W. (1997) · Blood · doi:10.1182/blood.v90.10.3962 · Cited by 290
Nathwani, A. C., Gray, J. T., McIntosh, J., Ng, C. Y. C., Zhou, J., Spence, Y., Cochrane, M., Gray, E., Tuddenham, E. G. D., & Davidoff, A. M. (2007) · Blood · doi:10.1182/blood-2006-03-010181 · Cited by 272
Miao, C. H., Ohashi, K., Patijn, G. A., Meuse, L., Ye, X., Thompson, A. R., & Kay, M. A. (2000) · Molecular Therapy · doi:10.1006/mthe.2000.0075 · Cited by 246
Davidoff, A. M., Ng, C. Y. C., Zhou, J., Spence, Y., & Nathwani, A. C. (2003) · Blood · doi:10.1182/blood-2002-09-2889 · Cited by 244
Sustained correction of bleeding disorder in hemophilia B mice by gene therapy
Wang, L., Takabe, K., Bidlingmaier, S. M., Ill, C. R., & Verma, I. M. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.7.3906 · Cited by 222
Davidoff, A. M., Gray, J. T., Ng, C. Y. C., Zhang, Y., Zhou, J., Spence, Y., Bakar, Y., & Nathwani, A. C. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2004.12.022 · Cited by 218
Adeno-Associated Virus Vectors in Clinical Trials
Carter, B. J. (2005) · Human Gene Therapy · doi:10.1089/hum.2005.16.541 · Cited by 206
Monahan, P., Samulski, R., Tazelaar, J., Xiao, X., Nichols, T., Bellinger, D., Read, M., & Walsh, C. (1998) · Gene Therapy · doi:10.1038/sj.gt.3300548 · Cited by 202
Self-citationJiang, H., Lillicrap, D., Patarroyo-White, S., Liu, T., Qian, X., Scallan, C. D., Powell, S., Keller, T., McMurray, M., Labelle, A., et al. (2006) · Blood · doi:10.1182/blood-2005-12-5115 · Cited by 200
Nakai, H., Storm, T. A., & Kay, M. A. (2000) · Journal of Virology · doi:10.1128/jvi.74.20.9451-9463.2000 · Cited by 194
Fu, H., Muenzer, J., Samulski, R. J., Breese, G., Sifford, J., Zeng, X., & McCarty, D. M. (2003) · Molecular Therapy · doi:10.1016/j.ymthe.2003.08.021 · Cited by 181
Self-citationBiology of AAV Serotype Vectors in Liver-Directed Gene Transfer to Nonhuman Primates
Gao, G., Lu, Y., Calcedo, R., Grant, R. L., Bell, P., Wang, L., Figueredo, J., Lock, M., & Wilson, J. M. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2005.08.017 · Cited by 170
Adeno-Associated Virus as a Vector for Liver-Directed Gene Therapy
Xiao, W., Berta, S. C., Lu, M. M., Moscioni, A. D., Tazelaar, J., & Wilson, J. M. (1998) · Journal of Virology · doi:10.1128/jvi.72.12.10222-10226.1998 · Cited by 166
Evaluation of Risks Related to the Use of Adeno-Associated Virus-Based Vectors
Tenenbaum, L., Lehtonen, E., & Monahan, P. E. (2003) · Current Gene Therapy · doi:10.2174/1566523034578131 · Cited by 163
Self-citationYan, C., Costa, R. H., Darnell, J. E., Jr., Chen, J. D., & Dyke, T. A. V. (1990) · The EMBO Journal · doi:10.1002/j.1460-2075.1990.tb08184.x · Cited by 151
The Transcriptional Activator Hepatocyte Nuclear Factor 6 Regulates Liver Gene Expression
Samadani, U., & Costa, R. H. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.11.6273 · Cited by 144
Miao, C. H., Nakai, H., Thompson, A. R., Storm, T. A., Chiu, W. S., Snyder, R. O., & Kay, M. A. (2000) · Journal of Virology · doi:10.1128/jvi.74.8.3793-3803.2000 · Cited by 144
Posttranslational modifications of recombinant myotube-synthesized human factor IX
Arruda, V. R., Hagstrom, J. N., Deitch, J. S., Heiman-Patterson, T. D., Camire, R. M., Chu, K. C., Fields, P. A., Herzog, R. W., Couto, L. B., Larson, P. J., et al. (2001) · Blood · doi:10.1182/blood.v97.1.130 · Cited by 117
Long-Term Efficacy of Adeno-Associated Virus Serotypes 8 and 9 in Hemophilia A Dogs and Mice
Sarkar, R., Mucci, M., Addya, S., Tetreault, R., Bellinger, D. A., Nichols, T. C., & Kazazian, H. H. (2006) · Human Gene Therapy · doi:10.1089/hum.2006.17.427 · Cited by 109
Wu, J., Zhao, W., Zhong, L., Han, Z., Li, B., Ma, W., Weigel-Kelley, K. A., Warrington, K. H., & Srivastava, A. (2007) · Human Gene Therapy · doi:10.1089/hum.2006.088 · Cited by 108
Wang, J., Xie, J., Lu, H., Chen, L., Hauck, B., Samulski, R. J., & Xiao, W. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702778104 · Cited by 100
Self-citationRole of Intron I in Expression of the Human Factor IX Gene
Kurachi, S., Hitomi, Y., Furukawa, M., & Kurachi, K. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.10.5276 · Cited by 91
Xu, D., McCarty, D. M., Fernandes, A., Fisher, M. H., Samulski, R. J., & Juliano, R. L. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2004.12.019 · Cited by 88
Self-citationGao, G., Lü, Y., Sun, X., Johnston, J., Calcedo, R., Grant, R. L., & Wilson, J. M. (2006) · Journal of Virology · doi:10.1128/jvi.00526-06 · Cited by 77
Hafenrichter, D. G., Wu, X., Rettinger, S. D., Kennedy, S., Flye, M. W., & Ponder, K. P. (1994) · Blood · doi:10.1182/blood.v84.10.3394.3394 · Cited by 72
Hafenrichter, D. G., Wu, X., Rettinger, S., et al. (1994) · Blood · doi:10.1182/blood.v84.10.3394.bloodjournal84103394 · Cited by 64
Sarkar, R., Xiao, W., & Kazazian, H. H. (2003) · Journal of Thrombosis and Haemostasis · doi:10.1046/j.1538-7836.2003.00096.x · Cited by 57
Creation of a mouse expressing defective human factor IX
Jin, D., Zhang, T.-P., Gui, T., Stafford, D. W., & Monahan, P. E. (2004) · Blood · doi:10.1182/blood-2004-01-0138 · Cited by 54
Self-citationLe, M., Okuyama, T., Cai, S.-R., Kennedy, S. C., Bowling, W. M., Flye, M. W., & Ponder, K. P. (1997) · Blood · doi:10.1182/blood.v89.4.1254 · Cited by 54
Zhong, L., Chen, L., Li, Y., Qing, K., Weigel-Kelley, K. A., Chan, R. J., Yoder, M. C., & Srivastava, A. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.07.018 · Cited by 45
Efficient gene delivery to human and rodent islets with double-stranded (ds) AAV-based vectors
Rehman, K. K., Wang, Z., Bottino, R., Balamurugan, A. N., Trucco, M., Li, J., Xiao, X., & Robbins, P. D. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302530 · Cited by 44
Zhang, T. P., Jin, D.-Y., Wardrop, R. M., Gui, T., Maile, R., Frelinger, J. A., Stafford, D. W., & Monahan, P. E. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302881 · Cited by 38
Self-citationNotley, C. R. P., Killoran, A., Cameron, C. L., Wynd, K., Hough, C. A., & Lillicrap, D. (2002) · Human Gene Therapy · doi:10.1089/10430340260201671 · Cited by 32
Hurt, M. M., Bowman, T. L., & Marzluff, W. F. (1991) · Molecular and Cellular Biology · doi:10.1128/mcb.11.6.2929 · Cited by 31
Efficient expression of protein coding genes from the murine U1 small nuclear RNA promoters.
Bartlett, J. S., Sethna, M., Ramamurthy, L., Gowen, S. A., Samulski, R. J., & Marzluff, W. F. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.17.8852 · Cited by 26
Self-citationHaut, D. D., & Pintel, D. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.3.1834-1843.1998 · Cited by 25
Globin gene transcripts can utilize histone gene 3′ end processing signals
Whitelaw, E., Coates, A., & Proudfoot, N. J. (1986) · Nucleic Acids Research · doi:10.1093/nar/14.17.7059 · Cited by 17
Haut, D. D., & Pintel, D. J. (1999) · Virology · doi:10.1006/viro.1999.9696 · Cited by 9
Gene therapy expression vectors based on the clotting Factor IX promoter
Hoag, H. M., Gore, J., Barry, D. A., & Mueller, C. R. (1999) · Gene Therapy · doi:10.1038/sj.gt.3300985 · Cited by 9
Cited by
Engineering adeno-associated virus vectors for gene therapy
Li, C., & Samulski, R. J. (2020) · Nature Reviews Genetics · doi:10.1038/s41576-019-0205-4 · Cited by 1,175
Self-citationEffect of genome size on AAV vector packaging
Wu, Z., Yang, H., & Colosi, P. (2010) · Molecular Therapy · doi:10.1038/mt.2009.255 · Cited by 1,029
Self-citationEmerging issues in AAV-mediated in vivo gene therapy
Colella, P., Ronzitti, G., & Mingozzi, F. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.11.007 · Cited by 881
Self-complementary AAV vectors; advances and applications
McCarty, D. M. (2008) · Molecular Therapy · doi:10.1038/mt.2008.171 · Cited by 515
Gray, S. J., Foti, S. B., Schwartz, J. W., Bachaboina, L., Taylor-Blake, B., Coleman, J., Ehlers, M. D., Zylka, M. J., McCown, T. J., & Samulski, R. J. (2011) · Human Gene Therapy · doi:10.1089/hum.2010.245 · Cited by 420
“Thus, a major challenge in effectively using scAAV vectors has been to combine minimal promoter, intron, and polyadenylation [poly(A)] elements in order to maximize the remaining space for the transgene-coding sequence (Wu et al., 2008).”
BackgroundSelf-citation
Metadata
- Authors
- Wu, Z., Sun, J., Zhang, T., Yin, C., Yin, F., Van Dyke, T., Samulski, R. J., & Monahan, P. E.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Monahan, Paul E
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2008-02
- Volume
- 16
- Issue
- 2
- Pages
- 280-289
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W1980491559
- Cited by
- 153
- References
- 50
- Citations by year
- 2026: 4 · 2025: 8 · 2024: 3 · 2023: 6 · 2022: 7 · 2021: 8 · 2020: 11 · 2019: 5 · 2018: 6 · 2017: 10 · 2016: 10 · 2015: 5 · 2014: 11 · 2013: 6 · 2012: 8
- FWCI
- 4.64
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor, 3171 d)
- Locations
- Molecular Therapy (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Heart, Lung, and Blood Institute (P01-HL66973, P01HL066973)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- self-complementary AAV vectors, hemophilia B, factor IX, liver-directed gene delivery, cis-regulatory elements, codon usage, GC content, hepatocyte transduction
- MeSH terms
- Dependovirus, Animals, Base Composition, Hemophilia B, Codon, Factor IX, Genetic Vectors, Humans, Immunohistochemistry, Liver, Male, Mice, Inbred C57BL, Transcription, Genetic, Blotting, Southern, Genetic Therapy, Gene Expression, In Situ Hybridization, Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.